A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

Detalles Bibliográficos
Autores principales: Komrokji, Rami S., Carraway, Hetty E., Germing, Ulrich, Wermke, Martin, Zeidan, Amer M., Fu, Eric, Rüter, Björn, Burkard, Ute, Osswald, Annika, Foran, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614517/
https://www.ncbi.nlm.nih.gov/pubmed/35734924
http://dx.doi.org/10.3324/haematol.2021.280500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614517/
https://www.ncbi.nlm.nih.gov/pubmed/35734924
http://dx.doi.org/10.3324/haematol.2021.280500

Ejemplares similares